
Technology
DNAtrix has a proprietary and versatile platform that enables the rapid creation of novel clinic-ready immunotherapies.
Learn More >
November 22, 2021DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting
September 14, 2021DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer
June 9, 2021DNAtrix to Present at the Raymond James Human Health Innovations Conference
DNAtrix is developing virus-driven immunotherapies to treat cancer. DNAtrix’s unique technology platform is based on an engineered version of the adenovirus (common cold virus) that was made to selectively infect and kill cancer cells while leaving healthy cells unharmed. DNAtrix’s therapies are being designed to eliminate cancer by directly killing cancer cells, awakening the immune system and driving an immune response against tumors. DNAtrix has therapies in multiple clinical trials for cancers with urgent need for novel approaches. Learn More >
DNAtrix has a proprietary and versatile platform that enables the rapid creation of novel clinic-ready immunotherapies.
Learn More >
A pipeline of innovative immunotherapies is being developed for the treatment of a variety of aggressive cancers.
Learn More >
Clinical trials of DNAtrix therapies are ongoing for adult and pediatric cancer patients.
Learn More >
Virus artwork by Luke Jerram